Choroideremia Research Foundation Acquires Spark Therapeutics, Inc., CHM Gene Therapy Assets, Advances Data Analysis
CRF acquired Spark Therapeutics, Inc.’s SPK-7001 CHM gene therapy assets and is analyzing long-term data to identify key clinical measures for development. SPRINGFIELD, MA, UNITED STATES, January 23, 2026 /EINPresswire.com/ -- In 2025, Choroideremia …